Merck & Co. Inc (6MK STU) stock market data APIs
€68.2781
0.38(0.6%)
as of July 4, 2025
Try our APIs with
free plan!
Merck & Co. Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for 6MK.SG.
Prev. Close
68.2781
Open
68.6542
High
68.2781
Low
68.6542
52 wk Range
64.9488-115.2725
Market Cap
162 424 M
Dividends (Yield)
0.0235
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Merck & Co. Inc data using free add-ons & libraries
Get Merck & Co. Inc Fundamental Data
Merck & Co. Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck & Co. Inc News
New
Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings
Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings Global pharmaceutical company Merck (NYSE:MRK) will be reporting results tomorrow before market hours. Here’s what to expect. ...
Merck & Co., Inc. (MRK): Among Prem Watsa’s Stock Picks With Highest Potential
We recently compiled a list of Billionaire Prem Watsa's 10 Stock Picks With Highest Potential.In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against Prem Wat...
Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?
Merck MRK will report its first-quarter 2024 earnings on April 24, before market open. The Zacks Consensus Estimate for first-quarter sales and earnings is pegged at $15.48 billion and $2.16 per share...
Health Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
Approval is based on the results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial KIRKLAND, QC, April 22, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
